Skip to content

KRM Ayurveda IPO Allotment: Check Status, GMP, Listing Date

KRM Ayurveda IPO Allotment Status Update

The basis of allotment for the KRM Ayurveda IPO is expected to be finalised today, Tuesday, January 27, 2026. The IPO closed for subscription on Friday, January 24, 2026, and witnessed strong investor interest, with the issue being oversubscribed by an impressive 74.27 times.

Once the allotment is finalised, applicants can check their KRM Ayurveda IPO allotment status online through the official websites of the NSE and Skyline Financial Services, which is the registrar for the issue.

KRM Ayurveda IPO Details

The KRM Ayurveda IPO was a ₹77.49 crore public issue consisting entirely of a fresh issue of 57 lakh equity shares. There was no offer-for-sale (OFS) component in the issue.

The IPO was offered in a price band of ₹128 to ₹135 per share, with a lot size of 1,000 shares. It was open for subscription from Wednesday, January 22, to Friday, January 24, 2026.

The company plans to utilise the IPO proceeds for capital expenditure related to the construction and development of telemedicine operational facilities, purchase of CRM software and hardware infrastructure, strengthening human resources, repayment or prepayment of certain loans, meeting working capital requirements, and for general corporate purposes.

KRM Ayurveda IPO GMP and Listing Outlook

KRM Ayurveda’s unlisted shares continued to trade at a strong premium in the grey market on Tuesday. As per market sources tracking unofficial trades, the shares were quoted at around ₹154 per share, indicating a grey market premium (GMP) of ₹19, or approximately 14.07% over the upper end of the issue price.

The shares of KRM Ayurveda are scheduled to be listed on the NSE SME platform on Thursday, January 29, 2026. Based on current grey market trends, the IPO is expected to make a strong debut.

If the prevailing GMP trend continues, the stock may offer listing gains of over 14%. However, investors should note that the grey market is unregulated, and GMP should not be treated as a guaranteed indicator of actual listing performance.

Back To Top